{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:13:17Z","timestamp":1793945597905,"version":"4.8.0"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The treatment landscape for patients with chronic lymphocytic leukemia (CLL) has changed considerably with the introduction of very effective oral targeted therapies (such as Bruton tyrosine kinase inhibitors and venetoclax) and next-generation anti-CD20 monoclonal antibodies (such as obinutuzumab). These agents lead to improved outcomes in patients with CLL, even among those with high-risk features, such as del17p13 or\n                    <jats:italic>TP53<\/jats:italic>\n                    mutation and unmutated immunoglobulin heavy chain (\n                    <jats:italic>IGHV<\/jats:italic>\n                    ) genes. Selecting the right treatment for the right patient requires consideration of disease characteristics and prior treatment sequence, as well as patient preferences and comorbidities. The CLL-International Prognostic Index (CLL-IPI) remains the best-validated tool in predicting the time to first therapy among previously untreated patients, which guides selection for early intervention efforts. This review summarizes our current approach to the management of CLL, right from the time of diagnosis through relapsed disease.\n                  <\/jats:p>","DOI":"10.1038\/s41408-022-00756-9","type":"journal-article","created":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T03:05:48Z","timestamp":1669691148000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Chronic lymphocytic leukemia treatment algorithm 2022"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1292-3024","authenticated-orcid":false,"given":"Paul J.","family":"Hampel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3221-7314","authenticated-orcid":false,"given":"Sameer A.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,29]]},"reference":[{"key":"756_CR1","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBDO, Berti E, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 2022;36:1720\u201348.","journal-title":"Leukemia"},{"key":"756_CR2","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1182\/blood.2022015851","volume":"140","author":"E Campo","year":"2022","unstructured":"Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood 2022;140:1229\u201353.","journal-title":"Blood"},{"key":"756_CR3","doi-asserted-by":"crossref","unstructured":"Slager SL, Parikh SA, Achenbach SJ, Norman AD, Rabe KG, Boddicker NJ, et al. Progression and survival of monoclonal B-cell lymphocytosis (MBL): a screening study of 10,139 individuals. Blood. 2022;140:1702\u20139.","DOI":"10.1182\/blood.2022016279"},{"key":"756_CR4","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1182\/blood-2013-08-523704","volume":"123","author":"YK Shim","year":"2014","unstructured":"Shim YK, Rachel JM, Ghia P, Boren J, Abbasi F, Dagklis A, et al. Monoclonal B-cell lymphocytosis in healthy blood donors: an unexpectedly common finding. Blood 2014;123:1319\u201326.","journal-title":"Blood"},{"key":"756_CR5","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s41375-020-0799-8","volume":"35","author":"TD Shanafelt","year":"2021","unstructured":"Shanafelt TD, Kay NE, Parikh SA, Achenbach SJ, Lesnick CE, Hanson CA, et al. Risk of serious infection among individuals with and without low count monoclonal B-cell lymphocytosis (MBL). Leukemia 2021;35:239\u201344.","journal-title":"Leukemia"},{"key":"756_CR6","doi-asserted-by":"crossref","unstructured":"Parikh SA, Chaffee KG, Larson MC, Hampel PJ, Call TG, Ding W, et al. Outcomes of a large cohort of individuals with clinically ascertained high-count monoclonal B-cell lymphocytosis. Haematologica. 2018;103:e237\u201340.","DOI":"10.3324\/haematol.2017.183194"},{"key":"756_CR7","doi-asserted-by":"crossref","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for diagnosis, indications for treatment, response assessment and supportive management of chronic lymphocytic leukemia. Blood. 2018;131:2745\u201360.","DOI":"10.1182\/blood-2017-09-806398"},{"key":"756_CR8","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1080\/10428194.2020.1869966","volume":"62","author":"PJ Hampel","year":"2021","unstructured":"Hampel PJ, Parikh SA, Call TG. Incorporating molecular biomarkers into the continuum of care in chronic lymphocytic leukemia. Leuk Lymphoma. 2021;62:1289\u2013301.","journal-title":"Leuk Lymphoma"},{"key":"756_CR9","doi-asserted-by":"crossref","unstructured":"An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. The Lancet Oncol.17:779\u201390.","DOI":"10.1016\/S1470-2045(16)30029-8"},{"key":"756_CR10","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1080\/10428194.2016.1257791","volume":"58","author":"S Molica","year":"2017","unstructured":"Molica S, Giannarelli D, Levato L, Mirabelli R, Gentile M, Morabito F. Assessing time to first treatment in early chronic lymphocytic leukemia (CLL): a comparative performance analysis of five prognostic models with inclusion of CLL-international prognostic index (CLL-IPI). Leuk Lymphoma. 2017;58:1736\u20139.","journal-title":"Leuk Lymphoma"},{"key":"756_CR11","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1182\/blood-2016-07-728261","volume":"128","author":"M Gentile","year":"2016","unstructured":"Gentile M, Shanafelt TD, Rossi D, Laurenti L, Mauro FR, Molica S, et al. Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients. Blood 2016;128:2093\u20135.","journal-title":"Blood"},{"key":"756_CR12","doi-asserted-by":"publisher","first-page":"9506979","DOI":"10.1155\/2018\/9506979","volume":"2018","author":"C Munoz-Novas","year":"2018","unstructured":"Munoz-Novas C, Poza-Santaella M, Gonzalez-Gascon YMI, Hernandez-Sanchez M, Rodriguez-Vicente AE, Infante MS, et al. The International Prognostic Index for patients with chronic lymphocytic leukemia has the higher value in predicting overall outcome compared with the Barcelona-Brno biomarkers only prognostic model and the MD Anderson Cancer Center Prognostic Index. Biomed Res Int. 2018;2018:9506979.","journal-title":"Biomed Res Int"},{"key":"756_CR13","doi-asserted-by":"crossref","unstructured":"Langerbeins P, Zhang C, Robrecht S, Cramer P, Furstenau M, et al. The CLL12 trial: ibrutinib vs placebo in treatment-na\u00efve,early-stage chronic lymphocytic leukemia. Blood. 2022 13;139:177\u201387.","DOI":"10.1182\/blood.2021010845"},{"key":"756_CR14","first-page":"92","volume":"19","author":"E Muchtar","year":"2021","unstructured":"Muchtar E, Kay NE, Parikh SA. Early intervention in asymptomatic chronic lymphocytic leukemia. Clin Adv Hematol Oncol. 2021;19:92\u2013103.","journal-title":"Clin Adv Hematol Oncol"},{"key":"756_CR15","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.2217\/fon.15.95","volume":"11","author":"P Langerbeins","year":"2015","unstructured":"Langerbeins P, Bahlo J, Rhein C, Cramer P, Pflug N, Fischer K, et al. The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression. Future Oncol. 2015;11:1895\u2013903.","journal-title":"Future Oncol"},{"key":"756_CR16","unstructured":"Prevention CDC Recommended immunization schedule for adults aged 19 years or older, United States, 2018. https:\/\/www.cdc.gov\/vaccines\/schedules\/hcp\/imz\/adult.html#f5."},{"key":"756_CR17","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1200\/JOP.2013.000921","volume":"10","author":"AS Mansfield","year":"2014","unstructured":"Mansfield AS, Rabe KG, Slager SL, Schwager SM, Call TG, Brewer JD, et al. Skin cancer surveillance and malignancies of the skin in a community-dwelling cohort of patients with newly diagnosed chronic lymphocytic leukemia. J Oncol Pract. 2014;10:e1\u20134.","journal-title":"J Oncol Pract"},{"key":"756_CR18","doi-asserted-by":"crossref","unstructured":"Solomon BM, Chaffee KG, Moreira J, Schwager SM, Cerhan JR, Call TG, et al. Risk of non-hematologic cancer in individuals with high count monoclonal B-cell lymphocytosis (MBL). Leukemia. 2016;30:331\u20136.","DOI":"10.1038\/leu.2015.235"},{"key":"756_CR19","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","volume":"380","author":"K Fischer","year":"2019","unstructured":"Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380:2225\u201336.","journal-title":"N Engl J Med"},{"key":"756_CR20","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1056\/NEJMoa1817073","volume":"381","author":"TD Shanafelt","year":"2019","unstructured":"Shanafelt TD, Wang XV, Kay NE, Hanson CA, O\u2019Brien S, Barrientos J, et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381:432\u201343.","journal-title":"N Engl J Med"},{"key":"756_CR21","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","volume":"395","author":"JP Sharman","year":"2020","unstructured":"Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet 2020;395:1278\u201391.","journal-title":"Lancet"},{"key":"756_CR22","doi-asserted-by":"crossref","unstructured":"Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018.","DOI":"10.1056\/NEJMoa1812836"},{"key":"756_CR23","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1158\/1078-0432.CCR-08-1630","volume":"15","author":"D Rossi","year":"2009","unstructured":"Rossi D, Cerri M, Deambrogi C, Sozzi E, Cresta S, Rasi S, et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res. 2009;15:995\u20131004.","journal-title":"Clin Cancer Res"},{"key":"756_CR24","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1182\/blood-2008-04-154070","volume":"112","author":"T Zenz","year":"2008","unstructured":"Zenz T, Krober A, Scherer K, Habe S, Buhler A, Benner A, et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 2008;112:3322\u20139.","journal-title":"Blood"},{"key":"756_CR25","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1182\/blood-2013-11-539726","volume":"123","author":"D Rossi","year":"2014","unstructured":"Rossi D, Khiabanian H, Spina V, Ciardullo C, Bruscaggin A, Fam\u00e0 R, et al. Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. Blood 2014;123:2139\u201347.","journal-title":"Blood"},{"key":"756_CR26","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","volume":"343","author":"H Dohner","year":"2000","unstructured":"Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910\u20136.","journal-title":"N Engl J Med"},{"key":"756_CR27","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1002\/ajh.26595","volume":"97","author":"HJ Cherng","year":"2022","unstructured":"Cherng HJ, Khwaja R, Kanagal-Shamanna R, Tang G, Burger J, Thompson P, et al. TP53-altered chronic lymphocytic leukemia treated with firstline Bruton\u2019s tyrosine kinase inhibitor-based therapy: a retrospective analysis. Am J Hematol. 2022;97:1005\u201312.","journal-title":"Am J Hematol"},{"key":"756_CR28","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","volume":"376","author":"M Hallek","year":"2010","unstructured":"Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164\u201374.","journal-title":"Lancet"},{"key":"756_CR29","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","volume":"17","author":"B Eichhorst","year":"2016","unstructured":"Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016;17:928\u201342.","journal-title":"Lancet Oncol"},{"key":"756_CR30","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1056\/NEJMc2005943","volume":"383","author":"IE Ahn","year":"2020","unstructured":"Ahn IE, Tian X, Wiestner A. Ibrutinib for chronic lymphocytic leukemia with TP53 alterations. N Engl J Med. 2020;383:498\u2013500.","journal-title":"N Engl J Med"},{"key":"756_CR31","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1111\/bjh.17984","volume":"196","author":"JN Allan","year":"2022","unstructured":"Allan JN, Shanafelt T, Wiestner A, Moreno C, O\u2019Brien SM, Li J, et al. Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials. Br J Haematol. 2022;196:947\u201353.","journal-title":"Br J Haematol"},{"key":"756_CR32","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","volume":"6","author":"PM Barr","year":"2022","unstructured":"Barr PM, Owen C, Robak T, Tedeschi A, Bairey O, Burger JA, et al. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv. 2022;6:3440\u201350.","journal-title":"Blood Adv"},{"key":"756_CR33","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1182\/blood-2021-153146","volume":"138","author":"JA Woyach","year":"2021","unstructured":"Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, et al. Long-term results of alliance A041202 show continued advantage of ibrutinib-based regimens compared with bendamustine plus rituximab (BR) chemoimmunotherapy. Blood 2021;138:639. Supplement 1","journal-title":"Blood"},{"key":"756_CR34","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1182\/blood.2021014960","volume":"140","author":"TD Shanafelt","year":"2022","unstructured":"Shanafelt TD, Wang XV, Hanson CA, Paietta EM, O\u2019Brien S, Barrientos J, et al. Long-term outcomes for ibrutinib\u2013rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Blood 2022;140:112\u201320.","journal-title":"Blood"},{"key":"756_CR35","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1182\/blood-2021-152319","volume":"138","author":"P Hillmen","year":"2021","unstructured":"Hillmen P, Pitchford A, Bloor A, Broom A, Young M, Kennedy B, et al. Ibrutinib plus rituximab is superior to FCR in previously untreated CLL: results of the phase III NCRI FLAIR trial. Blood 2021;138:642. Supplement 1","journal-title":"Blood"},{"key":"756_CR36","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/s41375-021-01485-x","volume":"36","author":"JP Sharman","year":"2022","unstructured":"Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, et al. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-na\u00efve chronic lymphocytic leukemia. Leukemia 2022;36:1171\u20135.","journal-title":"Leukemia"},{"key":"756_CR37","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","volume":"23","author":"CS Tam","year":"2022","unstructured":"Tam CS, Brown JR, Kahl BS, Ghia P, Giannopoulos K, Jurczak W, et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol. 2022;23:1031\u201343.","journal-title":"Lancet Oncol"},{"key":"756_CR38","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1182\/blood-2018-10-879429","volume":"133","author":"JA Burger","year":"2019","unstructured":"Burger JA, Sivina M, Jain N, Kim E, Kadia T, Estrov Z, et al. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood 2019;133:1011\u20139.","journal-title":"Blood"},{"key":"756_CR39","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.1200\/JCO.21.01181","volume":"39","author":"O Al-Sawaf","year":"2021","unstructured":"Al-Sawaf O, Zhang C, Lu T, Liao MZ, Panchal A, Robrecht S, et al. Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study. J Clin Oncol. 2021;39:4049\u201360.","journal-title":"J Clin Oncol"},{"key":"756_CR40","unstructured":"Eichhorst B, Niemann C, Kater A, F\u00fcrstenau M, Tresckow JV, Zhang C, et al. Time-limited venetoclax-obinutuzumab +\/- Ibrutinib is superior to chemoimmunotherapy in frontline chronic lymphocytic leuKEMIA (CLL): PFS co-primary endpoint of the randomized phasE 3 GAIA\/CLL13 tRIAL. EHA2022; Vienna, Austria, 2022."},{"key":"756_CR41","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1182\/blood.2021014488","volume":"139","author":"CS Tam","year":"2022","unstructured":"Tam CS, Allan JN, Siddiqi T, Kipps TJ, Jacobs R, Opat S, et al. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. Blood 2022;139:3278\u201389.","journal-title":"Blood"},{"key":"756_CR42","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1200\/JCO.21.00807","volume":"39","author":"WG Wierda","year":"2021","unstructured":"Wierda WG, Allan JN, Siddiqi T, Kipps TJ, Opat S, Tedeschi A, et al. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. J Clin Oncol. 2021;39:3853\u201365.","journal-title":"J Clin Oncol"},{"key":"756_CR43","doi-asserted-by":"publisher","first-page":"EVIDoa2200006","DOI":"10.1056\/EVIDoa2200006","volume":"1","author":"AP Kater","year":"2022","unstructured":"Kater AP, Owen C, Moreno C, Follows G, Munir T, Levin M-D, et al. Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities. NEJM Evid 2022;1:EVIDoa2200006.","journal-title":"NEJM Evid"},{"key":"756_CR44","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1111\/j.1532-5415.2008.01935.x","volume":"56","author":"F Salvi","year":"2008","unstructured":"Salvi F, Miller MD, Grilli A, Giorgi R, Towers AL, Morichi V, et al. A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients. J Am Geriatrics Soc. 2008;56:1926\u201331.","journal-title":"J Am Geriatrics Soc"},{"key":"756_CR45","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1182\/blood-2015-03-634394","volume":"127","author":"JC Byrd","year":"2016","unstructured":"Byrd JC, Flynn JM, Kipps TJ, Boxer M, Kolibaba KS, Carlile DJ, et al. Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia. Blood 2016;127:79\u201386.","journal-title":"Blood"},{"key":"756_CR46","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1080\/10428194.2017.1410890","volume":"59","author":"ND Gay","year":"2018","unstructured":"Gay ND, Kozin E, Okada C, Danilov AV, Spurgeon S. Obinutuzumab monotherapy in previously untreated chronic lymphocytic leukemia. Leuk Lymphoma. 2018;59:2258\u201360.","journal-title":"Leuk Lymphoma"},{"key":"756_CR47","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1200\/JCO.21.01210","volume":"39","author":"JC Byrd","year":"2021","unstructured":"Byrd JC, Hillmen P, Ghia P, Kater AP, Chanan-Khan A, Furman RR, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol. 2021;39:3441\u201352.","journal-title":"J Clin Oncol"},{"key":"756_CR48","unstructured":"Hillmen P, Eichhorst B, Brown JR, Lamanna N, O\u2019Brien S, Tam CS, et al. First interim analysis of alpine study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma. 2021. European Hematology Association Congress; Virtual."},{"key":"756_CR49","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1182\/blood.2020010146","volume":"138","author":"XV Wang","year":"2021","unstructured":"Wang XV, Hanson CA, Tschumper RC, Lesnick CE, Braggio E, Paietta EM, et al. Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib. Blood 2021;138:2810\u201327.","journal-title":"Blood"},{"key":"756_CR50","doi-asserted-by":"crossref","unstructured":"Yucai W, Kari GR, Michael SB, Min S, Curtis AH, Susan MS, et al. The role of 18F-FDG-PET in detecting Richter\u2019s transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor. Haematologica 2020;105:2675\u20138.","DOI":"10.3324\/haematol.2019.240564"},{"key":"756_CR51","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1002\/ajh.25956","volume":"95","author":"L Jondreville","year":"2020","unstructured":"Jondreville L, Krzisch D, Chapiro E, Nguyen-Khac F. The complex karyotype and chronic lymphocytic leukemia: prognostic value and diagnostic recommendations. Am J Hematol. 2020;95:1361\u20137.","journal-title":"Am J Hematol"},{"key":"756_CR52","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1182\/hematology.2020000118","volume":"2020","author":"A Lipsky","year":"2020","unstructured":"Lipsky A, Lamanna N. Managing toxicities of Bruton tyrosine kinase inhibitors. Hematol Am Soc Hematol Educ Program. 2020;2020:336\u201345.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"756_CR53","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1182\/hematology.2020000120","volume":"2020","author":"K Fischer","year":"2020","unstructured":"Fischer K, Al-Sawaf O, Hallek M. Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia. Hematol Am Soc Hematol Educ Program. 2020;2020:357\u201362.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"756_CR54","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/ajh.25638","volume":"94","author":"T Munir","year":"2019","unstructured":"Munir T, Brown JR, O\u2019Brien S, Barrientos JC, Barr PM, Reddy NM, et al. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94:1353\u201363.","journal-title":"Am J Hematol"},{"key":"756_CR55","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1400376","volume":"371","author":"JC Byrd","year":"2014","unstructured":"Byrd JC, Brown JR, O\u2019Brien S, Barrientos JC, Kay NE, Reddy NM, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:213\u201323.","journal-title":"N Engl J Med"},{"key":"756_CR56","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1200\/JCO.19.03355","volume":"38","author":"P Ghia","year":"2020","unstructured":"Ghia P, Pluta A, Wach M, Lysak D, Kozak T, Simkovic M, et al. ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020;38:2849\u201361.","journal-title":"J Clin Oncol"},{"key":"756_CR57","doi-asserted-by":"publisher","first-page":"7538","DOI":"10.1200\/JCO.2022.40.16_suppl.7538","volume":"40","author":"W Jurczak","year":"2022","unstructured":"Jurczak W, Pluta A, Wach M, Lysak D, Simkovic M, Kriachok I, et al. Acalabrutinib versus rituximab plus idelalisib or bendamustine in relapsed\/refractory chronic lymphocytic leukemia: ASCEND results at 4 years of follow-up. J Clin Oncol. 2022;40:7538. 16_suppl","journal-title":"J Clin Oncol"},{"key":"756_CR58","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","volume":"378","author":"JF Seymour","year":"2018","unstructured":"Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D\u2019Rozario J, Assouline S, et al. Venetoclax\u2013rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378:1107\u201320.","journal-title":"N Engl J Med"},{"key":"756_CR59","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1182\/blood.2021015014","volume":"140","author":"JF Seymour","year":"2022","unstructured":"Seymour JF, Kipps TJ, Eichhorst BF, D\u2019Rozario J, Owen CJ, Assouline S, et al. Enduring undetectable MRD and updated outcomes in relapsed\/refractory CLL after fixed-duration venetoclax-rituximab. Blood 2022;140:839\u201350.","journal-title":"Blood"},{"key":"756_CR60","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1200\/JCO.2017.76.6840","volume":"36","author":"S Stilgenbauer","year":"2018","unstructured":"Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S, et al. Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial. J Clin Oncol. 2018;36:1973\u201380.","journal-title":"J Clin Oncol"},{"key":"756_CR61","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/01.HS9.0000843476.36877.79","volume":"6","author":"S Stilgenbauer","year":"2022","unstructured":"Stilgenbauer S, Tausch E, Roberts AW, Davids MS, Eichhorst B, Hallek M, et al. S146: venetoclax in patients with chronic lymphocytic leukemia with 17P deletion: 6-year follow-up and genomic analyses in a pivotal phase 2 trial. HemaSphere. 2022;6:47\u20138.","journal-title":"HemaSphere"},{"key":"756_CR62","doi-asserted-by":"crossref","unstructured":"Mato AR, Nabhan C, Thompson MC, Lamanna N, Brander DM, Hill B, et al. Toxicities and outcomes of 621 ibrutinib-treated chronic lymphocytic leukemia patients in the United States: a real-world analysis. Haematologica. 2018;103:874\u20139.","DOI":"10.3324\/haematol.2017.182907"},{"key":"756_CR63","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1080\/10428194.2019.1602268","volume":"60","author":"PJ Hampel","year":"2019","unstructured":"Hampel PJ, Ding W, Call TG, Rabe KG, Kenderian SS, Witzig TE, et al. Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice. Leuk Lymphoma. 2019;60:2712\u20139.","journal-title":"Leuk Lymphoma"},{"key":"756_CR64","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1002\/cam4.2998","volume":"9","author":"SA Parikh","year":"2020","unstructured":"Parikh SA, Achenbach SJ, Call TG, Rabe KG, Ding W, Leis JF, et al. The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice. Cancer Med. 2020;9:3390\u20139.","journal-title":"Cancer Med"},{"key":"756_CR65","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.3324\/haematol.2020.272500","volume":"106","author":"KA Rogers","year":"2021","unstructured":"Rogers KA, Thompson PA, Allan JN, Coleman M, Sharman JP, Cheson BD, et al. Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed\/refractory chronic lymphocytic leukemia. Haematologica 2021;106:2364\u201373.","journal-title":"Haematologica"},{"key":"756_CR66","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1097\/01.HS9.0000850412.41160.5d","volume":"6","author":"M Shadman","year":"2022","unstructured":"Shadman M, Flinn IW, Kingsley EC, Freeman B, Levy MY, Cultrera J, et al. PB1890: zanubrutinib in acalabrutinib-intolerant patients (PTS) with B-cell malignancies. HemaSphere. 2022;6:1769\u201370.","journal-title":"HemaSphere"},{"key":"756_CR67","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1182\/blood.2018884940","volume":"135","author":"JC Byrd","year":"2020","unstructured":"Byrd JC, Wierda WG, Schuh A, Devereux S, Chaves JM, Brown JR, et al. Acalabrutinib monotherapy in patients with relapsed\/refractory chronic lymphocytic leukemia: updated phase 2 results. Blood 2020;135:1204\u201313.","journal-title":"Blood"},{"key":"756_CR68","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1182\/blood-2016-06-719294","volume":"129","author":"IE Ahn","year":"2017","unstructured":"Ahn IE, Underbayev C, Albitar A, Herman SE, Tian X, Maric I, et al. Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. Blood 2017;129:1469\u201379.","journal-title":"Blood"},{"key":"756_CR69","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","volume":"35","author":"JA Woyach","year":"2017","unstructured":"Woyach JA, Ruppert AS, Guinn D, Lehman A, Blachly JS, Lozanski A, et al. BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia. J Clin Oncol. 2017;35:1437\u201343.","journal-title":"J Clin Oncol"},{"key":"756_CR70","doi-asserted-by":"crossref","unstructured":"Blombery P, Thompson ER, Lew TE, Tiong IS, Bennett R, Cheah CY, et al. Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross resistance. Blood Adv. 2022;6:5589\u201392.","DOI":"10.1182\/bloodadvances.2022008325"},{"key":"756_CR71","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S1470-2045(17)30909-9","volume":"19","author":"JA Jones","year":"2018","unstructured":"Jones JA, Mato AR, Wierda WG, Davids MS, Choi M, Cheson BD, et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018;19:65\u201375.","journal-title":"Lancet Oncol"},{"key":"756_CR72","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/bjh.15802","volume":"185","author":"TA Eyre","year":"2019","unstructured":"Eyre TA, Kirkwood AA, Gohill S, Follows G, Walewska R, Walter H, et al. Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis. Br J Haematol. 2019;185:656\u201369.","journal-title":"Br J Haematol"},{"key":"756_CR73","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.3324\/haematol.2018.193615","volume":"103","author":"AR Mato","year":"2018","unstructured":"Mato AR, Thompson M, Allan JN, Brander DM, Pagel JM, Ujjani CS, et al. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Haematologica 2018;103:1511\u20137.","journal-title":"Haematologica"},{"key":"756_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00721-6","volume":"12","author":"PJ Hampel","year":"2022","unstructured":"Hampel PJ, Rabe KG, Call TG, Ding W, Leis JF, Chanan-Khan AA, et al. Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib. Blood Cancer J. 2022;12:124.","journal-title":"Blood Cancer J"},{"key":"756_CR75","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1634\/theoncologist.2020-0388","volume":"25","author":"PJ Hampel","year":"2020","unstructured":"Hampel PJ, Call TG, Rabe KG, Ding W, Muchtar E, Kenderian SS, et al. Disease flare during temporary interruption of ibrutinib therapy in patients with chronic lymphocytic leukemia. Oncologist. 2020;25:974\u201380.","journal-title":"Oncologist"},{"key":"756_CR76","doi-asserted-by":"publisher","first-page":"4508","DOI":"10.1182\/bloodadvances.2020002454","volume":"4","author":"PJ Hampel","year":"2020","unstructured":"Hampel PJ, Cherng H-JJ, Call TG, Ding W, Khanlari M, McPhail ED, et al. Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib. Blood Adv. 2020;4:4508\u201311.","journal-title":"Blood Adv"},{"key":"756_CR77","doi-asserted-by":"publisher","first-page":"E57","DOI":"10.1002\/ajh.25690","volume":"95","author":"PJ Hampel","year":"2020","unstructured":"Hampel PJ, Call TG, Ding W, Muchtar E, Kenderian SS, Wang Y, et al. Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare. Am J Hematol. 2020;95:E57\u2013E60.","journal-title":"Am J Hematol"},{"key":"756_CR78","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","volume":"397","author":"AR Mato","year":"2021","unstructured":"Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study. Lancet 2021;397:892\u2013901.","journal-title":"Lancet"},{"key":"756_CR79","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1182\/blood-2021-148672","volume":"138","author":"JA Woyach","year":"2021","unstructured":"Woyach JA, Flinn IW, Awan FT, Eradat H, Brander DM, Tees M, et al. Preliminary efficacy and safety of MK-1026, a non-covalent inhibitor of wild-type and C481S mutated Bruton tyrosine kinase, in B-cell malignancies: a phase 2 dose expansion study. Blood 2021;138:392. Supplement 1","journal-title":"Blood"},{"key":"756_CR80","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.1158\/1078-0432.CCR-19-3815","volume":"26","author":"AR Mato","year":"2020","unstructured":"Mato AR, Roeker LE, Jacobs R, Hill BT, Lamanna N, Brander D, et al. Assessment of the efficacy of therapies following venetoclax discontinuation in CLL reveals BTK inhibition as an effective strategy. Clin Cancer Res. 2020;26:3589\u201396.","journal-title":"Clin Cancer Res"},{"key":"756_CR81","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1182\/blood.2020004782","volume":"135","author":"VS Lin","year":"2020","unstructured":"Lin VS, Lew TE, Handunnetti SM, Blombery P, Nguyen T, Westerman DA, et al. BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax. Blood 2020;135:2266\u201370.","journal-title":"Blood"},{"key":"756_CR82","doi-asserted-by":"publisher","first-page":"4553","DOI":"10.1182\/bloodadvances.2022007812","volume":"6","author":"MC Thompson","year":"2022","unstructured":"Thompson MC, Harrup RA, Coombs CC, Roeker LE, Pu JJ, Choi MY, et al. Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen. Blood Adv. 2022;6:4553\u20137.","journal-title":"Blood Adv"},{"key":"756_CR83","doi-asserted-by":"crossref","unstructured":"Thomalla D, Beckmann L, Grimm C, Oliverio M, Meder L, Herling CD, et al. Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies. Blood. 2022.","DOI":"10.1182\/blood.2021014304"},{"key":"756_CR84","doi-asserted-by":"publisher","first-page":"4054","DOI":"10.1182\/bloodadvances.2021005083","volume":"5","author":"TE Lew","year":"2021","unstructured":"Lew TE, Lin VS, Cliff ER, Blombery P, Thompson ER, Handunnetti SM, et al. Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition. Blood Adv. 2021;5:4054\u20138.","journal-title":"Blood Adv"},{"key":"756_CR85","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1182\/blood-2021-147599","volume":"138","author":"AR Mato","year":"2021","unstructured":"Mato AR, Pagel JM, Coombs CC, Shah NN, Lamanna N, Munir T, et al. Pirtobrutinib, a next generation, highly selective, non-covalent BTK inhibitor in previously treated CLL\/SLL: updated results from the phase 1\/2 BRUIN study. Blood 2021;138:391. Supplement 1","journal-title":"Blood"},{"key":"756_CR86","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/bjh.18357","volume":"199","author":"PJ Hampel","year":"2022","unstructured":"Hampel PJ, Rabe KG, Call TG, Ding W, Leis JF, Kenderian SS, et al. Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia. Br J Haematol. 2022;199:239\u201344.","journal-title":"Br J Haematol"},{"key":"756_CR87","doi-asserted-by":"publisher","first-page":"5124","DOI":"10.1182\/bloodadvances.2022007708","volume":"6","author":"JM Hyak","year":"2022","unstructured":"Hyak JM, Huang Y, Rogers KA, Bhat SA, Grever MR, Byrd JC, et al. Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes. Blood Adv. 2022;6:5124\u20137.","journal-title":"Blood Adv"},{"key":"756_CR88","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.1182\/bloodadvances.2020001956","volume":"4","author":"LE Roeker","year":"2020","unstructured":"Roeker LE, Dreger P, Brown JR, Lahoud OB, Eyre TA, Brander DM, et al. Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. Blood Adv. 2020;4:3977\u201389.","journal-title":"Blood Adv"},{"key":"756_CR89","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","volume":"602","author":"JJ Melenhorst","year":"2022","unstructured":"Melenhorst JJ, Chen GM, Wang M, Porter DL, Chen C, Collins MA, et al. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. Nature 2022;602:503\u20139.","journal-title":"Nature"},{"key":"756_CR90","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1182\/blood.2021011895","volume":"139","author":"T Siddiqi","year":"2022","unstructured":"Siddiqi T, Soumerai JD, Dorritie KA, Stephens DM, Riedell PA, Arnason J, et al. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed\/refractory CLL or SLL. Blood 2022;139:1794\u2013806.","journal-title":"Blood"},{"key":"756_CR91","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1182\/blood-2020-140622","volume":"136","author":"WG Wierda","year":"2020","unstructured":"Wierda WG, Dorritie KA, Munoz J, Stephens DM, Solomon SR, Gillenwater HH, et al. Transcend CLL 004: phase 1 cohort of lisocabtagene maraleucel (liso-cel) in combination with ibrutinib for patients with relapsed\/refractory (R\/R) chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL). Blood 2020;136:39\u201340.","journal-title":"Blood"},{"key":"756_CR92","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020;382:545\u201353.","journal-title":"N Engl J Med"},{"key":"756_CR93","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1002\/ajh.26585","volume":"97","author":"MJ Gordon","year":"2022","unstructured":"Gordon MJ, Ferrajoli A. Unusual complications in the management of chronic lymphocytic leukemia. Am J Hematol. 2022;97:S26\u2013S34.","journal-title":"Am J Hematol"},{"key":"756_CR94","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1182\/blood.2019003686","volume":"139","author":"E Porpaczy","year":"2022","unstructured":"Porpaczy E, J\u00e4ger U. How I manage autoimmune cytopenias in patients with lymphoid cancer. Blood 2022;139:1479\u201388.","journal-title":"Blood"},{"key":"756_CR95","doi-asserted-by":"crossref","unstructured":"Smyth E, Eyre TA, Cheah CY. Emerging therapies for the management of Richter transformation. J Clin Oncol. doi: 10.1200\/JCO.22.01028.","DOI":"10.1200\/JCO.22.01028"},{"key":"756_CR96","first-page":"348","volume":"18","author":"Y Wang","year":"2020","unstructured":"Wang Y, Ding W. Richter transformation of chronic lymphocytic leukemia in the era of novel agents. Clin Adv Hematol Oncol. 2020;18:348\u201357.","journal-title":"Clin Adv Hematol Oncol"}],"updated-by":[{"DOI":"10.1038\/s41408-022-00775-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000}}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00756-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00756-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00756-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T03:04:40Z","timestamp":1671678280000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00756-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,29]]},"references-count":96,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["756"],"URL":"https:\/\/doi.org\/10.1038\/s41408-022-00756-9","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,29]]},"assertion":[{"value":"25 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2022","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41408-022-00775-6","URL":"https:\/\/doi.org\/10.1038\/s41408-022-00775-6","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Research funding has been provided to the institution from Janssen, AstraZeneca, Merck, and Genentech for clinical studies in which Sameer A. Parikh is a principal investigator. Honoraria has been provided to the institution from Pharmacyclics, Merck, AstraZeneca, Genentech, Amgen, TG Therapeutics, Novalgen Limited, and AbbVie for Sameer A. Parikh\u2019s participation in consulting activities\/advisory board meetings.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"161"}}